COMPARING EFFICACY OF THE ANTIBIOTICS CONSIDERING NEW AGENTS USED TO TREAT ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS CAUSED BY MRSA: A NETWORK META-ANALYSIS
نویسندگان
چکیده
COMPARING EFFICACY OF THE ANTIBIOTICS CONSIDERING NEW AGENTS USED TO TREAT ACUTE BACTERIAL SKIN AND STRUCTURE INFECTIONS CAUSED BY MRSA: A NETWORK META-ANALYSIS
منابع مشابه
Comparative efficacy and safety of antibiotics used to treat acute bacterial skin and skin structure infections: Results of a network meta-analysis
OBJECTIVE This NMA compared the efficacy and safety between IV antibiotics that are used in the current standard of care for managing adult patients (≥18 years of age) with ABSSSI. METHODS Comparators were chosen on the basis that both direct and indirect comparisons between the interventions of interest could be performed. Outcomes of the analysis were selected on the basis that they are fre...
متن کاملSystematic review and network meta-analysis of tedizolid for the treatment of acute bacterial skin and skin structure infections caused by MRSA
BACKGROUND Tedizolid, the active moiety of tedizolid phosphate, is approved in the United States, the European Union, Canada and a number of other countries for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by certain susceptible bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). This network meta-analysis (NMA) evaluates the comparativ...
متن کاملClinical efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections (ABSSSI)
Acute bacterial skin and skin structure infections (ABSSSI) are a common disease causing patients to seek treatment through the health care system. With the continued increase of drug-resistant bacterial pathogens, these infections are becoming more difficult to successfully cure. Lipoglycopeptides have unique properties that allow the drug to remain active toward both common and challenging pa...
متن کاملTedizolid phosphate for the management of acute bacterial skin and skin structure infections: efficacy summary.
The novel oxazolidinone tedizolid phosphate is in late-stage development for acute bacterial skin and skin structure infections (ABSSSIs). Preclinical and phase 1 trials have shown that 200-mg once-daily tedizolid phosphate dosing achieves the appropriate pharmacokinetic goals for optimal antimicrobial effect, and a randomized phase 2 dose-ranging trial confirmed that tedizolid phosphate may be...
متن کاملEarly endpoints for acute bacterial skin and skin structure infections.
In this issue of the journal, Friedland et al. (4) present a retrospective analysis of the two CANVAS trials (3), employing the newer endpoints from the U.S. Food and Drug Administration (FDA) (7). First, they are to be congratulated for having the foresight to include sufficient measurements in their trial to allow the reanalysis even prior to the issuance of the new guidelines. The analysis e...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: ???? ??????? ???? ?????
سال: 2022
ISSN: ['2717-008X']
DOI: https://doi.org/10.52547/umj.32.12.927